Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT

Journal of Neurology

Volumn 245, Issue 1, 1998, Pages 14-20

  Tissingh, G ^a   Bergmans, P ^a   Booij, J ^b   Winogrodzka, A ^a   Van Royen, E A ^b   Stoof, J C ^a   Wolters, E C ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cocaine analogues; Dopamine transporter; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; LIGAND; TROPANE DERIVATIVE;

ADULT; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DISCRIMINANT ANALYSIS; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

ADULT; AGED; CARRIER PROTEINS; CASE-CONTROL STUDIES; COCAINE; CORPUS STRIATUM; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031910293     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050168     Document Type: Article

References (36)

1. Asenbaum S, Brücke T, Pirker W, et al (1997) Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's Disease. J Nucl Med 38 : 1-6
2. Bemheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20 : 415-455
3. 123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 24 : 68-71
4. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62 : 133-140
5. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 94 : 137-146
6. Carroll FI, Scheffel U, Dannals RF, Boja JW, Kuhar MJ (1995) Development of imaging agents for the dopamine transporter. Med Res Rev 15 : 419-444
7. Fahn S, Elton RL, and members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillan Healthcare Information, Florham Park, N.J., pp 153-163
8. Fang J, Yu PH (1994) Effect of L-deprenyl, its structural analogues and some mono-amine oxidase inhibitors on dopamine uptake. Neuropharmacology 33 : 763-768
9. Fearnley JM Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 : 2283-2301
10. Gibb WRG, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54 : 388-396
11. 2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - an autoradiography study. Brain Res 640 : 185-194
12. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298 : 27-30
13. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17 : 427-442
14. Hughes A, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336 : 32-34
15. Hughes AJ, Daniel SE, Kilford L. Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 : 181-184
16. 3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250 : 261-266
17. Innis RB (1994) Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease. Eur J Nucl Med 21 : 1-5
18. Innis RB, Seibyl JP, Scanley BE, et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 90: 11965-11969
19. Jankovic J, McDermott M, Carter J, et al (1990) Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 40 : 1529-1534
20. Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse 9 : 43-49
21. 18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 216 : 109-112
22. Kish SJ, Shannak K, Hornykiewics O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318 : 876-880
23. Koller WC, Langston JW, Rubble JP, et al (1991) Does a long preclinical period occur in Parkinson's disease? Neurology 41 [Suppl 2] : 8-13
24. Kuikka JT, Bergstrom KA, Vanninen E, Laulumaa V, Hartikainen P, Länsimies E (1993) Initial experience with single-photon emission tomography using iodine-123-labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. Eur J Nucl Med 20 : 783-786
25. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13 : 295-309
26. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46 : 23 1-237
27. Moody CA, Granneman JG, Bannon MJ (1996) Dopamine transporter binding in rat striutiim and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett 217 : 55-57
28. 123I]-2β-Carbomethoxy-3β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 34 : 3144-3146
29. Neumeyer JL, Wang S, Gao Y, et al (1994) N-Ω-Fluoroalkyl analogs of (1R)-2β-Carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37 : 1558-1561
30. 123I]β-CIT SPECT. Parkinsonism Rel Disord 1 : 47-51
31. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 : 589-598
32. 3H]GBR 12783 binding in vivo. Eur J Pharmacol 178 : 221-227
33. 123I]β-CIT Binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 22 : 985-991
34. Wiener HL, Hashim A, Lajtha A, Sershen H (1989) Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 163 : 191-194
35. Zetusky WJ, Jankovic J, Pirozzolo FJ (1985) The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 35 : 522-526
36. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13 : 290-296